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The DMT1 gene encodes divalent metal transporter 1, a membrane iron transport protein. Divalent metal transporter 1 influences
cellular iron availability, which might further affect aerobic exercise capacity. Short tandem repeat (STR) polymorphisms have been
used as genetic markers in the literature, yet the STR polymorphisms of the DMT1 gene have not been well studied. In this current
study, we explored the polymorphisms of the DMT1 gene in a group of elite long-distance runners and controls, by using the PCR-
RFLP (Restriction Fragment Length Polymorphism) and Gene scan technology. We found that the genotype frequency of the
homozygous 258 bp STR polymorphism of the DMT1 gene (258 bp/258 bp) was significantly higher in the athlete group than in
the controls (χ2 = 14:01, p = 0:006) so does the allele frequency of the 258 bp STR polymorphism (χ2 = 12:867, p = 0:008). These
data suggested that the STR polymorphism of the DMT1 gene might be correlated with aerobic exercise capacity and the 258 bp
homozygous (25 bp/258 bp) could be used as a molecular marker for the talent identification of elite long-distance runners.
1. Introduction
Divalent metal transporter 1 (DMT1) is a major membrane
transport protein, which uptakes nonheme iron within the
lumen [1]. The DMT1 gene is expressed in many human tis-
sues, such as the small intestine, kidney, liver, and lung [2]. It
is known that the human proximal small intestine is the main
site for iron absorption, in which iron element exists in the
form of Fe2+. Fe2+ could enter into blood circulation via the
mediation of Ferroportin1 (FPN1) and Hephaestin (HP) or
enter into epithelial cells with the mediation of DMT1 [3].
Iron element plays an important role in constituting Hemo-
globin (Hb) and Myoglobin (Mb). Therefore, iron element
is important for exercise, yet its function can be characterized
by duality [4]. A deficiency of iron element affects the maxi-
mal uptake of oxygen (VO2max) of athletes and is associated
with a decreased exercise capacity, due to the reduction in
protein synthesis, the decreased oxygen transporting and
storing capacity, and the fall of enzymatic activities and
hormones level, as well as the reduction in phosphorylation
capacity and decreased adenosine triphosphate (ATP)
production [5]. On the other hand, excessive iron element
also affects exercise ability. Free iron element induces the
production of free radicals, leading to an increase of human
lipid peroxidation level and even tissue damage. Thus, both
iron deficiency and iron excess can directly affect exercise
ability [6].
Human exercise ability has distinct individual differ-
ences, which have been attributed from both the Nurture
side (diet and training) [7, 8] and the Nature side (genetics)
[9–16]. The human DMT1 gene is located in 12q13, with 17
exons. The expression of the DMT1 gene depends on the
basis of the organism or cell iron status [17]. Lee et al. first
discovered 5 polymorphic sites in the third intron of the
human DMT1 gene, as well as 1 short tandem repeat (STR)
microsatellite polymorphism [18]. STR is a short tandem
repeat sequence, with its core sequence 2-6 bp in length.
STR mainly exists in the noncoding regions of the genome,
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which is related to the genetic recombination and gene
express regulation, and maintains genome stability [19].
The STR located in the gene exon region has been reported
to encode protein [20]. STR is widely existed in the genome,
with a low recombination rate. Because of its compliance
with Mendelian Inheritance, i.e., its codominant heredity,
STR is widely used in association studies including genetic
phenotype, gene mapping, genetic disease diagnosis, and
paternity tests. It is therefore known as the second generation
of genetic markers.
In this current study, we explored the STR microsatellite
polymorphisms of the DMT1 gene in elite long-distance run-
ners and the controls, with the aim to identity molecular
genetic markers for talent identification of elite long-
distance runners.
2. Materials and Methods
2.1. Research Subjects. The study has been approved by the
ethics committee of Beijing Sport University; all the partici-
pants have signed a consent form. The study has been con-
ducted according to the principles of the Declaration of
Helsinki [21].
For the athlete group, there are 123 elite long-distance
runners, all from the northern region of China, all in good
health, and all belonging to Han nationality. The details are
shown in Table 1.
For the control group, there are 102 college students from
Beijing Sport University, without any professional training,
all from the northern region of China, all in good health,
and all belonging to Han nationality. The details are shown
in Table 2.
2.2. Experimental Method. DNA was extracted using the
Wizard® Genomic DNA Purification Kit (A1125, Promega,
Wisconsin, USA). The STR polymorphism (rs2076732) of
the DMT1 gene was obtained from the NCBI SNP library.
The STR polymorphism is located in intron 3 of the DMT1
gene, with the repetitive sequence: (TA) 6/7 (CA) 11/12/13
CCCCATCTA (TATC) 3 (TCTG) 4/5 TCCG TCTA
5/6/7/9/10. The PCR primers were designed with the Primer
5.0 software and were synthesized by Sangon Biotech
(Shanghai, China). The primer sequences are as follows:
forward primer: 5′-ggaTGGCTCaagTTCagcag-3′ (TAMRA
fluorescent tags 5′ item); reverse primer: 5′-TGGGCTatg-
GTTGTGccaCTG-3′. The PCR amplification fragments are
262 bp in length (Figure 1).
The distribution of the DMT1 gene STR polymorphisms
was determined by the ABI 377 DNA Sequencer (Applied
Biosystems, Massachusetts, USA) with the GeneScan detec-
tion technology (Figure 2).
2.3. Data Analysis. Data was analyzed with the SPSS15.0. A
χ2 test was used to check if the genotype frequency and allele
frequency are in line with the Hardy-Weinberg equilibrium
and to analyze the differences of the allele frequencies and
genotype frequencies between the athlete group and the
control group. A p < 0:05 is considered significant.
3. Results
A Hardy-Weinberg equilibrium was obtained for each geno-
type distribution frequency (p > 0:05, data were shown in
Tables 3 and 4).
Table 1: Basic information of the athlete group.
Groups No. of people Age (year) Height (cm) Weight (kg)
Type of sports Athletic level
5, 10 km Marathon International National
Athlete (total) 123 23:10 ± 5:10 169:29 ± 7:50 55:53 ± 7:45 92 31 43 79
Athlete (male) 62 24:27 ± 11:87 174:95 ± 5:13 61:48 ± 4:77 47 15 11 51
Athlete (female) 61 20:84 ± 5:31 163:53 ± 4:56 49:48 ± 3:97 45 16 32 29
Note: data are expressed in average ± standard deviation.
Table 2: Basic information of the control group.
Groups No. of people Age (year) Height (cm) Weight (kg)
Controls (total) 102 20:31 ± 1:20 168:88 ± 8:11 62:84 ± 11:87
Controls (male) 52 20:29 ± 1:15 174:60 ± 5:88 68:36 ± 12:24
Controls (female) 50 20:33 ± 1:27 162:57 ± 4:86 56:80 ± 7:90
Note: data are expressed in average ± standard deviation.
262bp
Figure 1: A presentative agarose picture of the PCR product of the
DMT1 gene STR polymorphism.
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According to the χ2 test results, there were significant dif-
ferences in the 258 bp/258 bp genotype frequency between
the athlete group and the control group (χ2 = 14:011, p =
0:006). When the athletes were further categorized as the 5,
10 km group or the marathon group, the 258 bp/258 bp geno-
type frequency was significantly different between the 5,
10 km group and the control group (χ2 = 11:910, p = 0:017)
but did not reach significance between the marathon group
and the control group (χ2 = 5:762, p = 0:217). We then
checked whether there was a gender difference in the geno-
type frequency of the DMT1 STR polymorphism; we did
not find a significant difference between males and females
among the athlete group or the control group. However, we
did found that the 258 bp/258 bp genotype frequency was sig-
nificantly higher in the male athletes than in the male con-
trols and significantly higher in the female athletes than in
the female controls.
We then checked the allele frequency of the 258 bp allele,
which was significant differently between the athlete group
and the control group (χ2 = 12:867, p = 0:008, Table 5), as
well as the 5, 10 km group and the control group
(χ2 = 11:082, p = 0:021). There was no significant difference
in the frequency of the 258 bp allele between the marathon
group and the control group (χ2 = 5:516, p = 0:212). When
we further divided the athletes into males and females, the
allele frequency was significantly higher in the male athletes
and female athletes, when compared with the male controls
and female controls, respectively.
4. Discussion
In this current study, we explored the STR polymorphisms of
the DMT1 gene; we have identified six alleles: 254 bp, 256p,
258 bp, 260 bp, 262 bp, and 266 bp. There are five alleles
and a total of eight genotypes in the athlete group, while
the control group has six alleles and ten genotypes; both
groups are in line with the Hardy-Weinberg equilibrium. A
previous study reported three alleles (260 bp, 262 bp, and
264 bp) in eight healthy Caucasians, which included two
260 bp homozygous, two 264 bp homozygous, three
260/262 bp heterozygous, and one 260/264 bp heterozygous
[22]. This discrepancy could be due to the small sample size
of the previous study (only eight individuals). It is also possi-
ble that there could be differences with the distribution of
DMT1 STR polymorphisms between different ethnic groups
(Caucasians for the previous study and Asians for the current
study).
Data from this current study suggested that there was a
strong association between the DMT1 STR polymorphism
and likelihood of being elite long-distance runners. The
frequency of 258 bp homozygous was significantly higher in
the athlete group (55.29%) than in the control group
(41.04%), similar for the 5, 10 km athlete group (58.70%).
The expression of the DMT1 gene has been associated with
iron levels in the body, which might further affect aerobic
exercise capacity. Previous studies have reported an
increased iron loss in long-distance runners [23, 24]; iron loss
254/254bp 258/258bp 260/260bp 262/262bp
250 260 260 260255 255
254/258bp 254/262bp 256/260bp
250 260 265255 255 260260
258/260bp 258/262bp 258/266bp
255 260 255 260 260 270265
250
Figure 2: Representative picture of the GeneScan genotype data of the DMT1 gene STR polymorphism.
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can induce the expression of the DMT1 gene in theduode-
num cells [25], while moderate exercise can also increase
the expression of the DMT1 gene in duodenum cells [26].
Therefore, both iron deficiency and exercise can increase
the expression of the DMT1 gene, leading to an increased
duodenal iron absorption and iron endosome transportation,
which ensures the iron demand of the human body. In addi-
tion, the G>C transversion of the last nucleotide of the
human DMT1 gene exon has been associated with iron defi-
ciency erythropoiesis and a decreased Hb level [27]. Fleming
et al. have also found that the glycine-arginine mutation
(G185R) of the DMT1 gene reduced intestinal iron absorp-
tion in Belgrade rats [28].
No research to date has reported the function of the
DMT1 gene STR polymorphism; we reported the association
of the DMT1 gene STR polymorphism with the likelihood of
being elite long-distance runners. We speculate the mecha-
nisms of theDMT1 gene STR polymorphism influencing aer-
obic exercise ability through the regulation of DMT1 gene
expression, which further influence intestinal iron absorption
and iron status. It is known that iron status affects exercise
performance [29]. The prevalence of iron deficiency anemia
is higher in athletic populations than sedentary controls,
especially in long-distance runners [29]. While a moderate
iron supplementation is effective in preventing decline in
the iron status of female collegiate swimmers during a com-
petitive season [30], the STR polymorphisms might regulate
DMT1 gene expression via two possible mechanisms. (1)
The STR polymorphisms might lead to alternative splicing
of the DMT1 gene. A recent study has proposed that there
is a link between short tandem repeats and translation initia-
tion site selection in humans [31]. Previous studies have
reported the existence of isoforms of DMT1 mRNA [32,
33] and protein [33], suggesting alternative splicing of the
DMT1 gene. It is plausible that the STR polymorphisms lead
to alternative splicing of the DMT1 gene, which further
affects the expression of the DMT1 gene. (2) DMT1 might
interact with hepcidin to control iron homeostasis. Hepcidin
is the main iron regulatory hormone responsible for the
maintenance of iron homeostasis, which controls the absorp-
tion of dietary iron and the distribution of iron among tissues
and organs in the body [34]. Hepcidin level was reported to
increase significantly 3, 6, and 24 h post exercise and then
declined after that, returning to baseline at 72 h post exercise
[35, 36]. Hepcidin was reported to decrease after 3 weeks of
training in female runners [37] but increased after an inten-
sified training period in well-trained female long-distance
runners [38]. On the other hand, hepcidin treatment has
been shown to decrease DMT1 expression and iron uptake
in intestinal cells [39] and in mouse intestines [40], suggest-
ing the regulation of DMT1 by hepcidin. It is possible that
the STR polymorphisms affect the regulation capacity of
hepcidin on DMT1, which leads to varied DMT1 expression
and different exercise capacity.
There are several limitations for the current study. (1)We
only checked the STR polymorphisms of the DMT1 gene,
which are located at the intron region of the DMT1 gene.
There are a number of other DMT1 polymorphisms reported
previously, but we have not checked whether there is an
addictive effect of different polymorphisms. There were no
associations between DMT1 1303 C>A polymorphism in
the exon region and iron overload in Chinese Parkinson’s
disease patients [41]. The 1254T>C polymorphism in the
exon region of the DMT1 gene has been associated with Par-
kinson’s disease [42]. However, there is no study that
checked the effects of those two polymorphisms on the
expression of the DMT1 gene. On the other hand, another
intronic DMT1 polymorphism, DMT1 IVS4+44C>A, has
been associated with increased DMT1 gene expression and
iron level. The C allele of the DMT1 IVS4+44C>A polymor-
phism is more prevalent in Parkinson’s disease patients, a
population known to have elevated iron accumulation in
the substantia nigra, together with the increased expression
of DMT1 gene expression [41]. The DMT1 IVS4 C(+) allele
occurred more frequently in Wilson’s disease population
than in the healthy controls, while iron dyshomeostasis has
been characterized in Wilson’s disease [43]. The CC geno-
type of the DMT1 gene IVS4+44C>A polymorphism is
associated with increased risk of age-related macular degen-
eration, a condition related to increased reactive oxygen spe-
cies, which might be caused by the increased iron ions [44].
The AA genotype of the DMT1 IVS4+44C>A polymorphism
has reported a four-fold increase of the risk of iron deficiency
anemia in children with celiac disease [45]. However, a previ-
ous study did not find significant differences in the
Table 5: The allele distribution of the DMT1 gene STR polymorphism.
Groups No. of people
Allele (bp)
254 256 258 260 262 266
Athlete (total) 123 54 (21.95) 1 (0.41) 179 (72.76)∗∗ 4 (1.63) 8 (3.25) —
Athlete (male) 62 29 (23.39) 0 (0.00) 89 (71.77)# 1 (0.81) 5 (4.03) —
Athlete (female) 61 25 (20.49) 1 (0.82) 90 (73.77)& 3 (2.46) 3 (2.46) —
5, 10 km group 92 36 (19.57) 1 (0.54) 138 (75.00)∗ 3 (1.63) 6 (3.26) —
Marathon group 31 18 (29.03) 0 (0.00) 41 (66.13) 1 (1.61) 2 (3.23) —
Control (total) 134 56 (20.90) 1 (0.37) 172 (64.18) 12 (4.48) 26 (9.70) 1 (0.37)
Control (male) 70 26 (18.57) 0 (0.00) 92 (65.71) 8 (5.71) 14 (10.00) 0 (0.00)
Control (female) 64 30 (23.44) 1 (0.78) 80 (62.50) 4 (3.13) 12 (9.38) 1 (0.78)
Note: data are shown in N (%); ∗p < 0:05 when compared with the control group; ∗∗p < 0:01 when compared with the control group; #p < 0:05 when compared
with the male controls.
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prevalence of the DMT1 IVS4+44C>A polymorphism in the
hereditary hemochromatosis cohort when compared with
the control group [46]. It would be important to investigate
the effect of more than one polymorphism of the DMT1 gene
on exercise capacity simultaneously, especially checking the
possible haplotype on exercise capacity in future studies. (2)
We have not checked the serum iron level or tissue iron level.
There is currently no report about the effects of DMT1 STR
polymorphisms on serum iron levels, while the effects of
the DMT1 gene on serum iron level are not conclusive. Mice
lacking intestinal DMT1 gene have shown to have extremely
low blood iron level [47]. However, patients with DMT1
mutations (GTG deletion in exon 5 and G→T substitution
in exon 8) have normal serum iron level but with a severe
liver iron overload [48]. Another mutation of theDMT1 gene
(SCL11A2) has been associated with a slight increase of
serum iron level, again with severe liver iron overload [49].
Together, these studies suggested that a change in DMT1
gene expression could lead to dysregulation of iron level in
blood and tissue, but the exact effects depend on the nature
of the polymorphism or mutation. Further studies are war-
ranted to investigate the effects of different DMT1 polymor-
phisms on serum and tissue iron levels.
5. Conclusion
The frequencies of the 258/258 bp homozygous genotype and
258 bp alleles are significantly higher in the elite long-
distance runners than in the control group; the DMT1 gene
STR polymorphism 258/258 bp genotype may be used as a
molecular marker for the talent identification of the elite
long-distance runners in Asian population.
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